Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Charles River raises annual profit view as it sells underperforming assets February 25, 20261:00 PM UTCUpdated ago By Reuters Feb 25 (Reuters) - Contract drug developer Charles River Laboratories (CRL.N), opens new tab raised its 2026 profit forecast on Wednesday, after it announced the sales of some underperforming assets to peer IQVIA (IQV.N), opens new tab and private equity firm GI Partner ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Have you evaluated the performance of Charles River Laboratories' (CRL) international operations during the quarter that concluded in December 2025? Considering the extensive worldwide presence of this medical research equipment and services provider, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal facto ...

Management views New Approach Methodologies (NAMS) and AI as long-term enabling technologies rather than immediate disruptors to regulated safety assessment environments.Manufacturing segment growth was hindered by the loss of a major commercial cell therapy client, though Microbial Solutions maintained strong performance across all testing platforms.Discovery Services volume declines impacted DSA revenue, while pricing and mix remained stable across the broader segment.The acquisition of KF Cambodia is a s ...

Shares of Charles River Laboratories International, Inc. ( CRL ) have been a mixed performer over the past year, trading essentially flat. That said, it has been a rollercoaster ride for investors, as shares have been negatively impacted by fears around FDA efforts to phaseOver fifteen years of experience making contrarian bets based on my macro view and stock-specific turnaround stories to garner outsized returns with a favorable risk/reward profile. If you want me to cover a specific stock or have a quest ...

Core Insights - Charles River Laboratories International, Inc. (CRL) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.39, a decrease of 10.2% year over year, but exceeded the Zacks Consensus Estimate by 2.51% [1] - On a GAAP basis, the company reported a loss of $5.62 per share compared to a loss of $4.22 in the same quarter last year [1] - Full-year 2025 EPS was $10.28, down 0.4% from the previous year, but surpassed the Zacks Consensus Estimate by 0.6% [1] Revenue Performance - Revenues for the fourth quarter totaled $994.2 million, beating the Zacks Consensus Estimate by 0.84%, but fell 0.8% from the previous year [2] - Full-year 2025 revenues were $4.02 billion, a decrease of 0.9% from the prior year, yet exceeded the Zacks Consensus Estimate by 0.2% [2] Segment Performance - Research Models and Services (RMS) revenues were $206.3 million, up 1% year over year, but down 0.9% organically [4] - Discovery and Safety Assessment (DSA) revenues amounted to $591.6 million, down 2% year over year and 3.3% organically [5] - Manufacturing Solutions revenues totaled $196.4 million, up 0.7% year over year, but down 2.1% organically [5] Margin Performance - Gross profit for the quarter was $414.4 million, an increase of 8.8% from the prior year, with a gross margin of 41.7%, up 368 basis points year over year [7] - Adjusted operating profit was $218.3 million, reflecting a 17.8% increase from the previous year, with an adjusted operating margin of 22%, up 347 basis points [7] Liquidity Position - At the end of the fourth quarter, cash and cash equivalents were $213.8 million, up from $194.6 million at the end of 2024 [10] - Cumulative net cash provided by operating activities was $737.6 million, compared to $734.6 million a year ago [10] 2026 Guidance - The company expects total revenues for 2026 to be at least flat to 1.5% growth, with the Zacks Consensus Estimate for 2025 revenues at $4.07 billion, implying 1.6% growth [11] - Adjusted EPS for 2026 is projected to be in the range of $10.70-$11.20, with the Zacks Consensus Estimate at $10.59 [11] Overall Assessment - CRL's fourth-quarter results showed earnings and revenues beating estimates, with significant improvement in DSA net bookings, indicating stabilization in biopharmaceutical demand [12] - The expansion of both gross and adjusted operating margins is viewed positively, and management is cautiously optimistic about continued positive demand trends in 2026 [12]

Charles River Laboratories (NYSE:CRL) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsBirgit Girshick - EVP and COOCasey Woodring - VP, Equity ResearchDave Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorEric Coldwell - Managing DirectorJames Foster - Chair, President and CEOLuke Sergott - Director - Healthcare Equity ResearchMichael Knell - VP and Chief Financial OfficerMichael Ryskin - Managing DirectorTodd Spencer - VP of Investor RelationsConference Call P ...

Charles River Laboratories (NYSE:CRL) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Company ParticipantsBirgit Girshick - EVP and COOCasey Woodring - VP, Equity ResearchDave Windley - Managing DirectorElizabeth Anderson - Senior Managing DirectorEric Coldwell - Managing DirectorJames Foster - Chair, President and CEOLuke Sergott - Director - Healthcare Equity ResearchMichael Knell - VP and Chief Financial OfficerMichael Ryskin - Managing DirectorTodd Spencer - VP of Investor RelationsConference Call P ...

Charles River Laboratories (NYSE:CRL) Q4 2025 Earnings call February 18, 2026 08:30 AM ET Speaker12I would now like to turn the conference over to your host, Todd Spencer, Vice President of Investor Relations. Please go ahead.Speaker14Good morning, and welcome to Charles River Laboratories' fourth quarter and full year 2025 earnings and 2026 guidance conference call and webcast. This morning, I am joined by Jim Foster, Chair, President, and Chief Executive Officer, Birgit Girshick, Executive Vice President ...

Financial Performance - In 2025, Charles River Laboratories reported total revenue of $4.0 billion, with the Discovery and Safety Assessment (DSA) segment contributing 59.8% of this revenue[20]. - The Research Models and Services (RMS) segment accounted for 21.1% of total revenue, employing approximately 4,140 individuals, including 190 science professionals with advanced degrees[23]. - The Manufacturing segment represented 19.1% of total revenue, with around 2,600 employees[26]. - The backlog for the RMS, DSA, and Manufacturing reportable segments was approximately $640 million, $1.9 billion, and $123 million, respectively, as of December 27, 2025, compared to $685 million, $2.0 billion, and $103 million as of December 28, 2024[122]. Global Operations - Charles River Laboratories operates over 120 sites in more than 20 countries, focusing on optimizing its global footprint by closing or consolidating approximately 12 additional sites over the next two years[20]. - The company has a global footprint with production facilities in 7 countries, strategically located near major biohubs and client concentrations[29]. Service Offerings - The company has a diverse portfolio of services that supports clients from target identification through non-clinical development, enhancing productivity and reducing costs[14]. - The company provides a full range of safety assessment studies required for regulatory submission across all therapeutic areas, establishing itself as a global leader in this field[43]. - The Discovery Services segment provides a full spectrum of services for drug candidate discovery, focusing on major therapeutic areas such as neuroscience, oncology, and immunology[42]. - The company offers a variety of flexible solutions in Research Model Services, including Insourcing Solutions, Genetically Engineered Models and Services, and Research Animal Diagnostic Services[34]. Acquisitions and Growth Strategy - In January 2026, the company acquired assets from K.F. (Cambodia) Ltd., integrating them into its DSA and RMS segments to enhance supply operations[33]. - Acquisitions are a key part of the growth strategy, with notable acquisitions including Explora BioLabs in fiscal 2022 and Noveprim in 2023, aimed at expanding the product and service portfolio[86]. - The company divested its Avian Vaccine Services business in 2022, which represented approximately 7% of the projected revenue for 2025, to focus on more profitable growth opportunities[89]. Employee and Workforce Management - As of December 27, 2025, the company employed approximately 19,700 individuals, with a workforce distribution of 59% in North America, 32% in Europe, and 7% in Asia[109]. - The company reduced its total headcount by approximately 2% since the end of 2024 as part of cost management initiatives[110]. - In fiscal 2025, the company hired over 2,600 people, with a voluntary turnover rate of approximately 10.1%[113]. - The company is committed to providing competitive compensation programs and performs pay equity audits in countries where legally required[118]. Research and Development - The company emphasizes the importance of research models in drug discovery, with a focus on maintaining high-quality standards and biosecurity[30]. - The development of new drugs requires an investment of up to $2.6 billion and exploration of 10,000 to 15,000 drug molecules to produce a single FDA-approved drug[15]. - The company has built a leading position in the production and sale of over 140 different stocks and strains of purpose-bred rodents, essential for drug discovery[23][28]. Safety and Compliance - The Safety Assessment facilities comply with GLP regulations and are regularly inspected by regulatory compliance monitoring authorities, ensuring high standards in safety testing[51]. - The company emphasizes the importance of identifying potential safety risks through a comprehensive offering of toxicology studies, including in vitro and in vivo research models[44]. - The company has established a Data Integrity Compliance Program to ensure proper oversight of electronic records and compliance with regulatory requirements[137]. Technological Advancements - The company is committed to optimizing operations and enhancing client experiences through technology, including the Apollo™ cloud-based platform for real-time data access[82]. - The company develops and implements scientifically-driven products and procedures, including computer software, to enhance its offerings and protect intellectual property rights[139]. Environmental and Safety Initiatives - In 2023, the company initiated a formal Environment, Health, Safety and Sustainability Assessment program, conducting 17 site assessments in the inaugural year[121]. - The company conducted 26 additional site program assessments in 2025 as part of its ongoing safety-first culture journey[121]. - The company emphasizes the importance of a healthy and safe workplace, launching a Safety-First Culture initiative in 2022[121]. Market Opportunities - The market for regulated safety assessment services is estimated to be over 60% outsourced, indicating a significant opportunity for Charles River Laboratories[19]. - The evolving biopharmaceutical R&D business model is expected to drive demand for the company's integrated offerings and expertise, enhancing efficiency and cost-effectiveness for clients[79].